People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mined Therapeutics, Inc. | — | Biotechnology | Series A | $7.0M | $141.4M | 2021 |
| Mercury Bio, Inc. | — | Biotechnology | Seed | $3.9M | $5.8M | 2025 |
Alex Koglin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alex Koglin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Seldin | 1 | 11 |
| John Tomes | 1 | 4 |
| Mike Rice | 1 | 2 |
| Thomas Nickoloff | 1 | 2 |
| Bruce McCormick | 1 | 1 |
| Kevin McDonald | 1 | 1 |
| Tuck Stibich | 1 | 1 |
| Steve Buelow | 1 | 1 |
| ANDREW SANDFORD | 1 | 1 |
| Paul Laur | 1 | 1 |
| Steve Kiziuk | 1 | 1 |
| Dana Barnard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.